- RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
- RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
- RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
- RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
- RedHill Announces New USPTO Patent Covering Talicia® Through 2034
- RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
- RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
More ▼
Key statistics
On Friday, Redhill Biopharma Ltd (RDHL:NAQ) closed at 0.4736, 84.28% above the 52 week low of 0.257 set on Oct 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.49 |
---|---|
High | 0.4989 |
Low | 0.4706 |
Bid | 0.4736 |
Offer | 0.48 |
Previous close | 0.4736 |
Average volume | 277.41k |
---|---|
Shares outstanding | 31.87m |
Free float | 31.67m |
P/E (TTM) | 0.1283 |
Market cap | 15.09m USD |
EPS (TTM) | 3.69 USD |
Data delayed at least 15 minutes, as of May 17 2024 20:59 BST.
More ▼